{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:33:00Z","timestamp":1759336380158},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T00:00:00Z","timestamp":1654128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,4,13]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To explore patient-reported outcomes (PROs) related to quality of life (QOL) in patients with rheumatoid arthritis (RA) who achieved clinical remission.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In the Institute of Rheumatology, Rheumatoid Arthritis dataset, RA patients &amp;gt;18\u2009years old who met the simplified disease activity index (SDAI) remission criteria in April 2017 were enrolled in this analysis. Pain-visual analogue scale (pain-VAS) (0\u2013100\u2009mm), patient\u2019s global assessment of disease activity (Pt-GA; 0\u2013100\u2009mm), Japanese version of the Health Assessment Questionnaire, duration of morning joint stiffness, and fatigue [Checklist Individual Strength 8R (CIS)] were the tools used to evaluate PROs. To assess the contribution of each PRO to the European QOL-5 Dimensions-5 Level (EQ-5D-5L) score, an analysis of variance was conducted.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among the 2443 patients with remission, the mean EQ-5D-5L was 0.9. The mean pain-VAS and Pt-GA were 7.2 and 7.4, respectively. Factors that significantly contributed to the EQ-5D-5L were pain-VAS (48.8%), CIS score (18.1%), and Pt-GA (15.6%). Around 82.5% of the variance in EQ-5D-5L was explained by the three PROs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This study demonstrated that pain-VAS, CIS, and Pt-GA were significant contributors to the EQ-5D-5L score in patients with RA who achieved the simplified disease activity index remission criteria.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/mr\/roac053","type":"journal-article","created":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T13:13:58Z","timestamp":1654175638000},"page":"496-502","source":"Crossref","is-referenced-by-count":4,"title":["Subjective symptoms contributing to the quality of life of rheumatoid arthritis patients with clinical remission from the IORRA database"],"prefix":"10.1093","volume":"33","author":[{"given":"Ryoko","family":"Sakai","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Institute of Rheumatology, Tokyo Women\u2019s Medical University Hospital , Tokyo, Japan"},{"name":"Division of Rheumatology, Department of Internal Medicine, Tokyo Women\u2019s Medical University School of Medicine , Tokyo, Japan"},{"name":"Division of Multidisciplinary Management of Rheumatic Diseases, Tokyo Women\u2019s Medical University School of Medicine , Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiichi","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Institute of Rheumatology, Tokyo Women\u2019s Medical University Hospital , Tokyo, Japan"},{"name":"Division of Rheumatology, Department of Internal Medicine, Tokyo Women\u2019s Medical University School of Medicine , Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eisuke","family":"Inoue","sequence":"additional","affiliation":[{"name":"Showa University Research Administration Center, Showa University , Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minako","family":"Sato","sequence":"additional","affiliation":[{"name":"Japan Drug Development and Medical Affairs, Eli Lilly Japan K.K. , Kobe, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaru","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Japan Drug Development and Medical Affairs, Eli Lilly Japan K.K. , Kobe, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsunori","family":"Ikari","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Institute of Rheumatology, Tokyo Women\u2019s Medical University Hospital , Tokyo, Japan"},{"name":"Division of Multidisciplinary Management of Rheumatic Diseases, Tokyo Women\u2019s Medical University School of Medicine , Tokyo, Japan"},{"name":"Department of Orthopedic Surgery, Tokyo Women\u2019s Medical University School of Medicine , Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisashi","family":"Yamanaka","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Tokyo Women\u2019s Medical University School of Medicine , Tokyo, Japan"},{"name":"Department of Rheumatology, Sanno Medical Center , Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayoshi","family":"Harigai","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Institute of Rheumatology, Tokyo Women\u2019s Medical University Hospital , Tokyo, Japan"},{"name":"Division of Rheumatology, Department of Internal Medicine, Tokyo Women\u2019s Medical University School of Medicine , Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,6,2]]},"reference":[{"key":"2023092217013905400_R1","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1080\/14397595.2017.1416940","article-title":"Residual symptoms and disease burden among patients with rheumatoid arthritis in remission or low disease activity: a systematic literature review","volume":"28","author":"Ishida","year":"2018","journal-title":"Mod Rheumatol"},{"key":"2023092217013905400_R2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1136\/annrheumdis-2020-217344","article-title":"EULAR definition of difficult-to-treat rheumatoid arthritis","volume":"80","author":"Nagy","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2023092217013905400_R3","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1136\/annrheumdis-2018-213687","article-title":"Characteristics of difficult-to-treat rheumatoid arthritis: results of an international survey","volume":"77","author":"Roodenrijs","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2023092217013905400_R4","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2014-000019","article-title":"Patient-reported outcomes as end points in clinical trials in rheumatoid arthritis","volume":"1","author":"Gossec","year":"2015","journal-title":"RMD Open"},{"key":"2023092217013905400_R5","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1136\/annrheumdis-2017-211259","article-title":"Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study","volume":"76","author":"Keystone","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2023092217013905400_R6","article-title":"Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs","volume":"21","author":"Strand","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2023092217013905400_R7","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1136\/annrheumdis-2016-209821","article-title":"Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON)","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2023092217013905400_R8","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-001040","article-title":"Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB\/IV trial","volume":"5","author":"Strand","year":"2019","journal-title":"RMD Open"},{"key":"2023092217013905400_R9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14397595.2019.1660028","article-title":"A large observational cohort study of rheumatoid arthritis, IORRA: providing context for today\u2019s treatment options","volume":"30","author":"Yamanaka","year":"2020","journal-title":"Mod Rheumatol"},{"key":"2023092217013905400_R10","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1080\/14397595.2016.1205799","article-title":"Pharmacoeconomic analysis of biological disease modifying antirheumatic drugs in patients with rheumatoid arthritis based on real-world data from the IORRA observational cohort study in Japan","volume":"27","author":"Tanaka","year":"2017","journal-title":"Mod Rheumatol"},{"key":"2023092217013905400_R11","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s10067-017-3634-5","article-title":"Characteristics and risk factors of lymphoproliferative disorders among patients with rheumatoid arthritis concurrently treated with methotrexate: a nested case-control study of the IORRA cohort","volume":"36","author":"Shimizu","year":"2017","journal-title":"Clin Rheumatol"},{"key":"2023092217013905400_R12","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis Rheum"},{"key":"2023092217013905400_R13","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2023092217013905400_R14","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1539\/joh.49.453","article-title":"Development of Japanese version of the checklist individual strength questionnaire in a working population","volume":"49","author":"Aratake","year":"2007","journal-title":"J Occup Health"},{"key":"2023092217013905400_R15","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/0022-3999(94)90099-X","article-title":"Dimensional assessment of chronic fatigue syndrome","volume":"38","author":"Vercoulen","year":"1994","journal-title":"J Psychosom Res"},{"key":"2023092217013905400_R16","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3109\/14397595.2015.1059983","article-title":"Profiles of EQ-5D utility scores in the daily practice of Japanese patients with rheumatoid arthritis; analysis of the IORRA database","volume":"26","author":"Hoshi","year":"2016","journal-title":"Mod Rheumatol"},{"key":"2023092217013905400_R17","doi-asserted-by":"crossref","first-page":"3761","DOI":"10.1002\/art.22190","article-title":"Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission: evidence from an imaging study may explain structural progression","volume":"54","author":"Brown","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2023092217013905400_R18","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1093\/rheumatology\/kep442","article-title":"Superiority of SDAI over DAS-28 in assessment of remission in rheumatoid arthritis patients using power Doppler ultrasonography as a gold standard","volume":"49","author":"Balsa","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"2023092217013905400_R19","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.semarthrit.2019.09.005","article-title":"Differences in disease activity measures in patients with rheumatoid arthritis who achieved DAS, SDAI, or CDAI remission but not Boolean remission","volume":"50","author":"Aletaha","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"2023092217013905400_R20","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1002\/ejp.1651","article-title":"The burden of pain in rheumatoid arthritis: impact of disease activity and psychological factors","volume":"24","author":"Vergne-Salle","year":"2020","journal-title":"Eur J Pain"},{"key":"2023092217013905400_R21","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1002\/acr.21932","article-title":"Association between fatigue and pain in rheumatoid arthritis: does pain precede fatigue or does fatigue precede pain?","volume":"65","author":"van Dartel","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2023092217013905400_R22","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1002\/acr.22787","article-title":"Predictors of fatigue in rheumatoid arthritis patients in remission or in a low disease activity state","volume":"68","author":"Olsen","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2023092217013905400_R23","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1007\/s10067-016-3246-5","article-title":"Predictors of remission, erosive disease and radiographic progression in a Colombian cohort of early onset rheumatoid arthritis: a 3-year follow-up study","volume":"35","author":"Quintana-Duque","year":"2016","journal-title":"Clin Rheumatol"},{"key":"2023092217013905400_R24","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1080\/14397595.2017.1422304","article-title":"Determinants of Patient\u2019s Global Assessment of Disease Activity and Physician\u2019s Global Assessment of Disease Activity in patients with rheumatoid arthritis: a post hoc analysis of overall and Japanese results from phase 3 clinical trials","volume":"28","author":"Kaneko","year":"2018","journal-title":"Mod Rheumatol"},{"key":"2023092217013905400_R25","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1080\/14397595.2016.1176310","article-title":"What factors affect discordance between physicians and patients in the global assessment of disease activity in rheumatoid arthritis?","volume":"27","author":"Cho","year":"2017","journal-title":"Mod Rheumatol"},{"key":"2023092217013905400_R26","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/acr.20685","article-title":"Determinants of discordance in patients\u2019 and physicians\u2019 rating of rheumatoid arthritis disease activity","volume":"64","author":"Khan","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2023092217013905400_R27","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3109\/03009742.2013.869831","article-title":"Discordance and accordance between patient\u2019s and physician\u2019s assessments in rheumatoid arthritis","volume":"43","author":"Furu","year":"2014","journal-title":"Scand J Rheumatol"},{"key":"2023092217013905400_R28","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/RHU.0b013e3182a2164f","article-title":"Comparison of physician and patient global assessments over time in patients with rheumatoid arthritis: a retrospective analysis from the RADIUS cohort","volume":"19","author":"Markenson","year":"2013","journal-title":"J Clin Rheumatol"},{"key":"2023092217013905400_R29","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1002\/art.34543","article-title":"Discrepancies between patients and physicians in their perceptions of rheumatoid arthritis disease activity","volume":"64","author":"Studenic","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2023092217013905400_R30","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-022-03091-5","article-title":"Patient-reported outcome measures of musculoskeletal symptoms and psychosocial factors in musicians: a systematic review of psychometric properties","author":"Roos","year":"2022","journal-title":"Qual Life Res"},{"key":"2023092217013905400_R31","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1093\/rheumatology\/key054","article-title":"Prevalence of sustained remission in rheumatoid arthritis: impact of criteria sets and disease duration, a Nationwide Study in Sweden","volume":"58","author":"Einarsson","year":"2019","journal-title":"Rheumatology (Oxford)"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roac053\/44251551\/roac053.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/33\/3\/496\/51715099\/roac053.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/33\/3\/496\/51715099\/roac053.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T17:31:28Z","timestamp":1695403888000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/33\/3\/496\/6598788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,2]]},"references-count":31,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,6,2]]},"published-print":{"date-parts":[[2023,4,13]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roac053","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,5,1]]},"published":{"date-parts":[[2022,6,2]]}}}